Literature DB >> 26659923

Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.

Seiji Bito1, Shigeki Miyata2, Kiyoshi Migita3, Mashio Nakamura4, Kazuhito Shinohara3, Tomotaro Sato3, Takeharu Tonai3, Motoyuki Shimizu3, Yasuhiro Shibata3, Kazuhiko Kishi3, Chikara Kubota3, Shinnosuke Nakahara3, Toshihito Mori3, Kazuo Ikeda3, Shusuke Ota3, Takeshi Minamizaki3, Shigeru Yamada3, Naofumi Shiota3, Masataka Kamei5, Satoru Motokawa6.   

Abstract

Platelet-activating antibodies, which recognize platelet factor 4 (PF4)/heparin complexes, induce spontaneous heparin-induced thrombocytopenia (HIT) syndrome or fondaparinux-associated HIT without exposure to unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). This condition mostly occurs after major orthopedic surgery, implying that surgery itself could trigger this immune response, although the mechanism is unclear. To investigate how surgery may do so, we performed a multicenter, prospective study of 2069 patients who underwent total knee arthroplasty (TKA) or hip arthroplasty. Approximately half of the patients received postoperative thromboprophylaxis with UFH, LMWH, or fondaparinux. The other half received only mechanical thromboprophylaxis, including dynamic (intermittent plantar or pneumatic compression device), static (graduated compression stockings [GCSs]), or both. We measured anti-PF4/heparin immunoglobulins G, A, and M before and 10 days after surgery using an immunoassay. Multivariate analysis revealed that dynamic mechanical thromboprophylaxis (DMT) was an independent risk factor for seroconversion (odds ratio [OR], 2.01; 95% confidence interval [CI], 1.34-3.02; P = .001), which was confirmed with propensity-score matching (OR, 1.99; 95% CI, 1.17-3.37; P = .018). For TKA, the seroconversion rates in patients treated with DMT but no anticoagulation and in patients treated with UFH or LMWH without DMT were similar, but significantly higher than in patients treated with only GCSs. The proportion of patients with ≥1.4 optical density units appeared to be higher among those treated with any anticoagulant plus DMT than among those not treated with DMT. Our study suggests that DMT increases risk of an anti-PF4/heparin immune response, even without heparin exposure. This trial was registered to www.umin.ac.jp/ctr as #UMIN000001366.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26659923      PMCID: PMC4768427          DOI: 10.1182/blood-2015-06-651620

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  Regulation of the immune response by antigen.

Authors:  R M Zinkernagel; H Hengartner
Journal:  Science       Date:  2001-07-13       Impact factor: 47.728

2.  Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia.

Authors:  Andreas Greinacher; Petra Eichler; Theresia Lietz; Theodore E Warkentin
Journal:  Blood       Date:  2005-10-15       Impact factor: 22.113

3.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

4.  Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis.

Authors:  G P Visentin; M Moghaddam; S E Beery; J G McFarland; R H Aster
Journal:  J Lab Clin Med       Date:  2001-07

5.  Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.

Authors:  Sarfraz Ahmad; Sylvia Haas; Debra A Hoppensteadt; Helen Lietz; Ulrike Reid; Norbert Bender; Harry L Messmore; Frank Misselwitz; Peter Bacher; Bhavna S Gaikwad; Walter P Jeske; Jeanine M Walenga; Jawed Fareed
Journal:  Thromb Res       Date:  2002-10-01       Impact factor: 3.944

6.  Impact of the patient population on the risk for heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J A Sheppard; P Horsewood; P J Simpson; J C Moore; J G Kelton
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

7.  Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.

Authors:  Nadine Martel; James Lee; Philip S Wells
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

8.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

9.  Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.

Authors:  Pierre Savi; Beng H Chong; Andreas Greinacher; Yves Gruel; John G Kelton; Theodore E Warkentin; Petra Eichler; Dick Meuleman; Maurice Petitou; Jean-Pascal Herault; Roger Cariou; Jean-Marc Herbert
Journal:  Blood       Date:  2004-09-23       Impact factor: 22.113

10.  Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia.

Authors:  A Greinacher; S Alban; V Dummel; G Franz; C Mueller-Eckhardt
Journal:  Thromb Haemost       Date:  1995-09       Impact factor: 5.249

View more
  14 in total

Review 1.  Induction of anti-PF4/heparin antibodies after arthroplasty for rheumatic diseases.

Authors:  Kiyoshi Migita; Tomoyuki Asano; Shuzo Sato; Satoru Motokawa
Journal:  Fukushima J Med Sci       Date:  2018-04-07

2.  Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia.

Authors:  Douglas B Cines; Serge V Yarovoi; Sergei V Zaitsev; Tatiana Lebedeva; Lubica Rauova; Mortimer Poncz; Gowthami M Arepally; Sanjay Khandelwal; Victoria Stepanova; Ann H Rux; Adam Cuker; Cecilia Guo; Linnette Mae Ocariza; Richard J Travers; Stephanie A Smith; Hugh Kim; James H Morrissey; Edward M Conway
Journal:  Blood Adv       Date:  2016-11-22

Review 3.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

Review 4.  Heparin-induced thrombocytopenia: research and clinical updates.

Authors:  Oluwatoyosi Onwuemene; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

6.  Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

Authors:  Sara C Meyer; Eva Steinmann; Thomas Lehmann; Patricia Muesser; Jakob R Passweg; Radek C Skoda; Dimitrios A Tsakiris
Journal:  Biomed Res Int       Date:  2017-06-18       Impact factor: 3.411

7.  Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity.

Authors:  Thi-Huong Nguyen; Nikolay Medvedev; Mihaela Delcea; Andreas Greinacher
Journal:  Nat Commun       Date:  2017-05-22       Impact factor: 14.919

8.  SERS spectral study of HAuCl4-cysteine nanocatalytic reaction and its application for detection of heparin sodium with label-free VB4r molecular probe.

Authors:  Xiaoliang Wang; Caina Jiang; Yanna Qin; Yutao Peng; Guiqing Wen; Aihui Liang; Zhiliang Jiang
Journal:  Sci Rep       Date:  2017-04-05       Impact factor: 4.379

9.  Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines.

Authors:  Rossella Marcucci; Marco Marietta
Journal:  Intern Emerg Med       Date:  2021-06-30       Impact factor: 3.397

Review 10.  Recent advances in understanding and management of acquired thrombocytopenia.

Authors:  Srikanth Nagalla; Ravindra Sarode
Journal:  F1000Res       Date:  2018-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.